nivolumab

Overview

Nivolumab (brand name Opdivo) is a therapeutic monoclonal antibody used in cancer treatment — a fully human immunoglobulin G4 (IgG4) immune checkpoint inhibitor directed against programmed cell death protein 1 (PD-1), a receptor expressed on the surface of activated T-lymphocytes. Developed by Bristol-Myers Squibb and first approved by the FDA in 2014, it is administered intravenously and has since been approved across a broad range of malignancies, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), hepatocellular carcinoma, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, bladder cancer, colorectal cancer, and classical Hodgkin lymphoma.

Mechanistically, nivolumab binds PD-1 and blocks its engagement by the ligands PD-L1 and PD-L2, which tumor cells and cells of the tumor microenvironment express to deliver inhibitory signals to infiltrating T cells. Interrupting PD-1/PD-L1 signaling relieves this suppression and restores T-cell effector function, including interferon gamma production and cytotoxic killing of tumor cells, thereby countering a central mechanism of immune evasion. Because the same axis dampens T-cell activity in non-malignant settings, PD-1 blockade has also been explored experimentally for immunosuppressive states such as sepsis. In clinical oncology, nivolumab is given as monotherapy or in combination regimens: paired with the anti-CTLA-4 antibody ipilimumab for dual checkpoint blockade, in which PD-1 inhibition reinvigorates exhausted effector T cells while CTLA-4 inhibition promotes T-cell priming and expansion; with tyrosine kinase inhibitors such as cabozantinib in renal cell carcinoma; or alongside conventional chemotherapy. These combinations generally increase antitumor activity at the cost of more frequent immune-related adverse events, such as checkpoint inhibitor pneumonitis, colitis, and endocrinopathies. Candidate predictors of benefit — PD-L1 expression, tumor mutational burden, and microsatellite instability — are widely studied, but their reliability differs by tumor type, and mechanisms of primary and acquired resistance to PD-(L)1 blockade remain an active area of investigation.

Recent Publications Summary (latest 30 papers)

Recent publications demonstrate nivolumab's expanding clinical role across diverse malignancies, with particular evidence in lung, renal, esophageal, and hepatic Cancers. In non-small cell lung cancer, adjuvant nivolumab following upfront surgery improved disease-free and overall survival in resected disease 42224490Jun, while neoadjuvant nivolumab plus chemotherapy achieved major pathological response in stage IB-IIIB disease 42262212Jun. Nivolumab plus ipilimumab provided clinical benefit in metastatic renal cell carcinoma with emerging stratification tools 42203341May, and dual checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma resulted in complete pathologic response with sustained disease control exceeding five years 42527032Jul. In esophageal malignancies, real-world outcomes confirmed ipilimumab plus nivolumab efficacy as first-line therapy 42289036Jun, with adjuvant nivolumab (CheckMate 577) showing benefit primarily in PD-L1-positive esophageal and gastroesophageal junction Cancers 41960736Apr.

Combination regimens pairing nivolumab with anti-angiogenic agents have emerged as standard approaches. cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma achieved an objective response rate of 45.2% and disease control rate of 93.6% across multiple histologic subtypes 42366526Jun. Nivolumab plus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma yielded an objective response rate of 32% with median overall survival of 26.6 months 42284972Jun. In biliary tract Cancers, nivolumab plus ipilimumab demonstrated acceptable tolerability in patients with intrahepatic cholangiocarcinoma and gallbladder cancer 42029635Apr. Across rare and ultra-rare malignancies, including gestational trophoblastic disease and neuroendocrine carcinomas, dual anti-CTLA-4 and anti-PD-1 blockade showed clinically meaningful activity 42106259May42240229Jun, with emerging triple approaches incorporating immunomodulatory agents such as NP-101 42012995Apr. Direct real-world comparisons between pembrolizumab plus lenvatinib and nivolumab plus cabozantinib in metastatic renal cell carcinoma provide practical evidence for treatment sequencing 42204034May.

Real-world data identify important clinical and biological predictors of outcome. Baseline opioid use was significantly associated with shorter treatment discontinuation time, with median time-to-discontinuation of 112 versus 284 days in non-users across multiple cancer types 42601535Aug. Early detriment analysis from CheckMate 227 and CheckMate 9LA revealed 40% rapid progression rates within three months of nivolumab plus ipilimumab initiation, with prognostic factors including high neutrophil-to-leukocyte ratio, tumor mutational burden <14 mutations per megabase, tumor PD-L1 <1%, and elevated baseline monocytic myeloid-derived suppressor cell levels 42360104Jun. Nivolumab rechallenge after first-line immune checkpoint inhibitor-based therapy and treatment sequencing strategies in advanced NSCLC were feasible with sustainable long-term outcomes 42385189Jul42071088May. For melanoma brain metastases, discontinuation within 24 months of nivolumab plus ipilimumab was evaluated to inform treatment duration in responding patients 42082273May.

biomarker-guided approaches and emerging mechanistic insights are refining nivolumab's application. PD-L1 expression was incorporated exploratively in trials including SUNNIFORECAST, which compared ipilimumab plus nivolumab with standard of care in papillary renal cell carcinoma 42235464Jun. COVID-19 vaccine type showed associations with nivolumab efficacy and safety in metastatic NSCLC, addressing clinical concerns regarding potential interactions with mRNA-based vaccines 42379805Jun. Temperature-dependent dynamics of PD-1 N-terminal loop motions influence nivolumab binding affinity, with dissociation lifetimes substantially longer at physiologic temperature (37°C) compared to fever temperature (39°C) 42199044May. Probiotics were investigated for restoring nivolumab or pembrolizumab effectiveness in esophageal cancer patients receiving proton pump inhibitors 42183961May. Immune-related adverse events documented include nivolumab-induced folliculitis 42060814Apr, immune-related sarcoidosis during dual checkpoint blockade 42527032Jul, and checkpoint inhibitor pneumonitis with pneumomediastinum in Hodgkin lymphoma 42274365Jun. Emerging therapeutic strategies include combination with moxibustion, which enhanced anti-PD-1 antibody efficacy in preclinical sepsis models through PD-1/PD-L1 pathway modulation 42307810Jun, and antiangiogenic nanoparticles combined with anti-PD-1 blockade in hepatocellular carcinoma models 42111772May.

What Changes, What Holds

1. Adjuvant and neoadjuvant nivolumab extend survival benefit in resected non-small cell lung cancer -- NEW DIRECTION

Adjuvant nivolumab after surgery improves disease-free and overall survival in resected disease 42224490Jun, expanding the entity's role beyond the metastatic settings the Overview emphasizes. Neoadjuvant nivolumab combined with chemotherapy achieves substantial pathological response in stage IB-IIIB disease 42262212Jun. The Overview addresses approved malignancies but not perioperative treatment windows; these findings establish nivolumab's efficacy in the resection-based paradigm for early-stage lung cancer.

2. cabozantinib and lenvatinib plus nivolumab achieve substantial responses in non-clear cell renal and hepatocellular carcinoma -- REINFORCES

cabozantinib plus nivolumab achieved 45.2% response rate in non-clear cell RCC 42366526Jun, while lenvatinib plus nivolumab yielded 32% responses with 26.6-month median survival in unresectable HCC 42284972Jun. The Overview establishes nivolumab's combination use with TKIs; these data extend that principle to additional malignancies rather than challenging the baseline's account of dual-agent synergy. Expansion to specific histologies and novel partners reinforces the established combination strategy.

3. Baseline opioid use predicts premature treatment discontinuation independent of tumor characteristics -- NEW DIRECTION

Opioid use at nivolumab initiation strongly predicted earlier discontinuation—median 112 days versus 284 days in non-users—across multiple cancer types 42601535Aug, identifying a patient-level factor the Overview does not discuss. Early rapid progression within three months was associated with high neutrophil-to-lymphocyte ratio, low tumor mutational burden, and suppressed T-cell markers 42360104Jun, narrowing prediction of futility and informing treatment selection beyond established mechanisms.

4. Fever reduces PD-1 binding affinity; new adverse events and drug interactions expand clinical monitoring -- NEW DIRECTION

Temperature-dependent PD-1 binding dynamics showed dissociation lifetimes substantially longer at 37°C than at 39°C 42199044May, suggesting fever may compromise efficacy—a pharmacological variable unaddressed in the Overview. New immune-related adverse events including folliculitis, sarcoidosis, and pneumomediastinum 42527032Jul42274365Jun expand the irAE spectrum beyond colitis and pneumonitis. Probiotics investigation for restoring efficacy in esophageal cancer patients receiving proton pump inhibitors addresses a drug interaction not yet discussed.

Overview update candidates: adjuvant and neoadjuvant nivolumab for resected NSCLC; opioid use as discontinuation predictor; expanded immune-related adverse event surveillance (folliculitis; sarcoidosis; pneumomediastinum).